Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of solifenacin oral suspension in pediatric overactive bladder
NL-OMON37421Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Solifenacin succinate suspension with Placebo (2 arms). Primary endpoint: Change from baseline to end of treatment in mean volume voided per micturition. Started Jul 2013; status: active, not recruiting.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON37421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37421.